ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 (e...
September 25 2018 - 07:00AM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of protein and
antibody therapeutics for life-threatening, drug-resistant
infectious diseases, today announced the Company will participate
in a symposium entitled “Exploring the Antibiotic Pipeline 2018”
and present new data on its lead drug candidate, CF-301
(exebacase), at IDWeek 2018, to be held from October 3-7, 2018, in
San Francisco.
The symposium will review novel antibiotics in
the pipeline including mechanism of action and clinical
applications, and the possible role of novel therapies against
antibiotic-resistant organisms, and will evaluate data from new
antimicrobial molecules in development. “We are pleased to have
been invited by the conference organizers to participate in the
IDWeek pipeline update this year,” said Cara Cassino, M.D., the
Company's Executive Vice President of Research and Development and
Chief Medical Officer. Dr. Cassino will discuss the Company’s lead
lysin product candidate, CF-301 (exebacase), currently being
studied in a Phase 2 clinical study as a potential novel therapy
for Staphylococcus aureus (Staph aureus) bacteremia including
endocarditis.
In addition, ContraFect will present new data
comparing the activity of CF-301 (exebacase) against Staph aureus
isolates from bacteremic patients enrolled in the ongoing Phase 2
study to contemporary surveillance isolates.
Symposium Details:
Symposium
Title: Exploring the Antibiotic
Pipeline 2018 Presenter: Cara Cassino, M.D.,
Chief Medical Officer and Executive Vice President of Research and
DevelopmentRoom: N Hall DTime and
Date: 2:00 – 3:15 pm PT, Thursday, October 4,
2018Additional information on the symposium can be accessed through
the IDWeek website.
Presentation Details:
Presentation
Title: Comparison of Lysin CF-301
(Exebacase) Activity Against S. aureus Isolates from Bacteremic
Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary
Surveillance Isolates Session Title: Novel
AgentsAbstract Number: 1342Room:
S Poster HallTime and Date: 12:30 – 1:45 pm PT,
Friday, October 5, 2018
The abstract can be accessed through the IDWeek website.
Following the meeting, the presentation poster will be available on
the ContraFect website.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing therapeutic protein and antibody
products for life-threatening, drug-resistant infectious diseases,
particularly those treated in hospital settings. An estimated
700,000 deaths worldwide each year are attributed to
antimicrobial-resistant infections. We intend to address life
threatening infections using our therapeutic product candidates
from our lysin and monoclonal antibody platforms to target
conserved regions of either bacteria or viruses (regions that are
not prone to mutation). ContraFect's initial product candidates
include new agents to treat antibiotic-resistant infections such as
MRSA (Methicillin-Resistant Staphylococcus aureus) and influenza.
ContraFect’s lead product candidate, exebacase (CF-301), is
currently in a Phase 2 clinical trial for the treatment of
Staphylococcus aureus (Staph aureus) bacteremia, including
endocarditis and is the first lysin to enter clinical studies in
the U.S. ContraFect is also conducting research focused on
the discovery of lysins to target Gram-negative bacteria.
About exebacase (CF-301):
Exebacase (CF-301) is a recombinant
bacteriophage-derived lysin with potent bactericidal activity
against Staph aureus, a major cause of blood stream infections, or
bacteremia. CF-301 has the potential to be a first-in-class
treatment for Staph aureus bacteremia. It has a novel, rapid,
and specific mechanism of bactericidal action against Staph aureus
and does not impact the body's natural bacterial flora. By
targeting a conserved region of the cell wall that is vital to
bacteria, resistance is less likely to develop to CF-301.
Combinations of CF-301 with standard of care antibiotics
significantly increased bacterial killing and survival in animal
models of disease when compared to treatment with antibiotics or
CF-301 alone. In addition, in vitro and in vivo experiments have
shown that CF-301 is highly active against biofilm infections.
CF-301 was licensed from The Rockefeller University and is being
developed at ContraFect. It is the first lysin to enter clinical
studies in the U.S.
Forward-Looking Statements:
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, our ability
to address life threatening infections using our therapeutic
product candidates from our lysin and monoclonal antibody platforms
to target conserved regions of either bacteria or viruses, whether
our initial product candidates can treat antibiotic-resistant
infections such as MRSA (Methicillin-resistant Staph aureus) and
influenza, our ability to continue research focused on lysins
targeting Gram-negative bacteria, whether CF-301 has potent
bactericidal activity against Staph aureus and whether it has the
potential to be a first-in-class treatment for Staph aureus
bacteremia, statements regarding CF-301 in vivo and in vitro study
results and new data, and information provided regarding
presentations at IDWeek. Forward-looking statements are statements
that are not historical facts, nor assurances of future
performance. Instead, they are based on ContraFect’s current
beliefs, expectations and assumptions regarding the future of its
business, future plans, strategies, projections, anticipated events
and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including those detailed in ContraFect's filings with the
Securities and Exchange Commission. Actual results may differ
from those set forth in the forward-looking statements. Important
factors that could cause actual results to differ include, among
others, our ability to develop treatments for drug-resistant
infectious diseases. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Matthew ShinsekiStern Investor RelationsTel: 212-362-1200Email:
matthew@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2023 to Mar 2024